CLAIMS

1. A salt of (*R)*-6-(5-fluoropyridin-2-yl)-8-methoxy-*N*-(1-(5-methyl-1,2,4-oxadiazol-3-yl) ethyl)quinazolin-4-amine selected from mesylate salt and esylate salt.

2. The salt according to claim 1, which is the crystalline mesylate salt hemihydrate form.

3. The salt according to claim 1 or 2, which is the crystalline mesylate salt Form 2 characterized by an X-ray powder diffraction pattern comprising characteristic peaks at 6.6, 11.8 and 19.2 ±0.2 degrees 2-theta.

4. The salt according to any one of claims 1 to 3, which is the crystalline mesylate salt Form 2 characterized by an X-ray powder diffraction pattern comprising characteristic peaks at 6.6, 9.3, 11.8, 19.2 and 27.4 ±0.2 degrees 2-theta.

5. The salt according to any one of claims 1 to 4, which is the crystalline mesylate salt Form 2 characterized by an X-ray powder diffraction pattern comprising characteristic peaks at 6.6, 9.3, 11.8, 18.1, 18.5, 19.2, 20.0, 22.4, 25.7, and 27.4 ±0.2 degrees 2-theta.

6. The salt according to claim 1, which is the crystalline esylate salt Form 1 characterized by an X-ray powder diffraction pattern comprising characteristic peaks at 5.8, 16.3 and 17.7 ±0.2 degrees 2-theta.

7. The salt according to claim 1 or 6, which is the crystalline esylate salt Form 1 characterized by an X-ray powder diffraction pattern comprising characteristic peaks at 5.8, 8.7, 16.3, 17.7 and 20.1 ±0.2 degrees 2-theta.

8. The salt according to any one of claims 1, 6 or 7, which is the crystalline esylate salt Form 1 characterized by an X-ray powder diffraction pattern comprising characteristic peaks at 5.8, 8.7, 16.3, 17.7, 20.1, 21.5, 22.3, 23.5, 25.1 and 29.1 ±0.2 degrees 2-theta.

9. The salt according to claim 1, which is selected from crystalline mesylate salt Form 2 and crystalline esylate salt Form 1 as defined in claims 3, 4 or 5 and 6, 7 or 8, respectively.

10. A pharmaceutical composition comprising the salt as defined in any one of claims 1 to 9, either alone or in combination with another one or more active ingredients, in admixture with one or more pharmaceutically acceptable carriers or excipients.

11. The pharmaceutical composition according to claim 10 for oral administration.

12. The salt according to any one of claims 1 to 9 or the pharmaceutical composition according to claim 10 or 11 for use as a medicament.

13. The salt according to any one of claims 1 to 9 or the pharmaceutical composition according to claim 10 or 11 for use in the treatment of any disease wherein the $P2X_3$ receptors are involved.

14. Use of the salt according to any one of claims 1 to 9 or the pharmaceutical composition

according to claim 10 or 11 in the preparation of a medicament for prevention and/or treatment of respiratory diseases including cough, sub-acute or chronic cough, treatment-resistant cough, idiopathic chronic cough, post-viral cough, iatrogenic cough, asthma, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and cough associated with respiratory diseases such as COPD, asthma and bronchospasm, preferably in the treatment of chronic cough.

15. A process for the preparation of a crystalline salt of (*R)*-6-(5-fluoropyridin-2-yl)-8-methoxy-*N*-(1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl)quinazolin-4-amine (compound A) selected from mesylate and esylate salt, comprising the steps of:

1) suspending compound A free base in a polar solvent or solvent mixture;
2) adding methanesulfonic or ethanesulfonic acid; and
3) isolating the resulting crystalline salt by filtration.

16. The process according to claim 15, wherein the polar solvent or solvent mixture is selected from the group consisting of acetone, tetrahydrofuran, isopropanol, water and mixtures thereof.

17. The process according to claim 16, comprising the steps of:

1) suspending compound A free base in a polar solvent or solvent mixture;
2) adding methanesulfonic acid;
   2a) drying the solution obtained in step 2) ;
   2b) suspending the solid obtained in step 2a) in a polar solvent or solvent mixture and adding an antisolvent thus obtaining the precipitation of a crystalline salt; and
3) isolating the resulting crystalline compound A mesylate salt by filtration.

18. The process according to claim 17, wherein in step 1) and step 2b) the polar solvent or solvent mixture is selected from the group consisting of acetone, tetrahydrofuran, isopropanol, water and mixtures thereof and in step 2b) the antisolvent is heptane.

19. The process according to any one of claims 15 to 18, further comprising the step of washing the filtered crystalline mesylate or esylate salt with one or more polar solvents or solvent mixture, preferably selected from the group consisting of acetone, tetrahydrofuran, isopropanol, water and mixtures thereof.

20. The process according to any one of claims 15 to 19, further comprising a step of recrystallizing the crystalline mesylate or esylate salt with a polar solvent or solvent mixture, preferably selected from the group consisting of acetone, tetrahydrofuran, isopropanol, water and mixtures thereof.

21. The process according to any one of claims 15 to 20, further comprising a step of recrystallizing the crystalline mesylate salt of compound A from a mixture of isopropanol

and water.

22. The process according to any one of claims 15 to 21, wherein the salt is crystalline mesylate salt Form 2.

23. The process according to any one of claims 15, 16, 19 or 20, wherein the salt is crystalline esylate salt Form 1.